Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Standard chemotherapy with cetuximab for treatment of colorectal cancer.

World journal of gastroenterology - 14 Jun 2015

Li Xin-Xiang, Liang Lei, Huang Li-Yong, Cai San-Jun

Abstract excerpt

AIM: To review and assess the evidence related to cetuximab treatment in metastatic colorectal cancer (mCRC) with regard to KRAS status. METHODS: PubMed, EMBASE, Cochrane database and American Society of Clinical Oncology meeting abstracts were searched for randomized controlled trials (RCTs) reporting the effect of KRAS status on efficacy of chemotherapy regimen with or without cetuximab in mCRC. Baseline...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cetuximab
Share to Chi-Square Distribution

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Molecular Targeted Therapy

Share to Proto-Oncogene Proteins p21(ras)

Share to Randomized Controlled Trials as Topic

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 26078581
DOI: 10.3748/wjg.v21.i22.7022
PMCID: PMC4462745

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Standard chemotherapy with cetuximab for treatment of colorectal cancer.PMID 26078581Read ↗

Impact of cetuximab in current treatment of metastatic colorectal cancer.Semantic proximity Read ↗

Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials.Semantic proximity Read ↗

Cetuximab Plus Various Chemotherapy Regimens for Patients with KRAS Wild-Type Metastatic Colorectal Cancer.Semantic proximity Read ↗

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.Semantic proximity Read ↗

Cetuximab plus chemotherapy as first-line treatment for metastatic colorectal cancer: effect of KRAS mutation on treatment efficacy in Taiwanese patients.Semantic proximity Read ↗

Cetuximab in the treatment of patients with colorectal cancer.Semantic proximity Read ↗

Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies.Semantic proximity Read ↗

Cetuximab/irinotecan-chemotherapy in KRAS wild-type pretreated metastatic colorectal cancer: a pooled analysis and review of literature.Semantic proximity Read ↗

How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?Semantic proximity Read ↗

Role of cetuximab in first-line treatment of metastatic colorectal cancer.Semantic proximity Read ↗

KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.Semantic proximity Read ↗

Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAFV600E-mutant metastatic and/or unresectable colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.